This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

Invacare Corporation
8/9/2022
Good morning, ladies and gentlemen, and thank you for standing by. Welcome to the Invercare second quarter 2022 conference call and webcast. After the management overview, we will open the call to questions. Investors and analysts interested in asking a question will need to dial in as questions cannot be submitted via the webcast. For the first part of the call, all phone lines have been placed on mute. This conference is being recorded Tuesday, August 9th, 2022. I will now turn the call over to Lois Lee, Invacare's Director of Treasury, Investor Relations and Corporate Communications.
Thank you. Joining me on today's call from Invacare are Matt Monaghan, Chairman, President and Chief Executive Officer, and Kathy Lenahan, Senior Vice President and Chief Financial Officer. Today we will be reviewing our second quarter 2022 financial results and providing investors with an update on our business outlook. To help investors follow along, we have created slides to accompany this webcast. For those dialing in, you can find a link to our webcast slide presentation at global.inricare.com slash investor dash relations. Further information can be found in our SEC filings. Before Matt begins, I'd like to note that during today's call, we may make forward-looking statements about the company that, by their nature, address matters that are uncertain. Actual future results may differ materially from those expressed in our statements today due to various uncertainties, and I refer you to the cautionary statement included on the second page of our webcast slides and in our second quarter earnings release. An explanation of the items discussed on today's call that are considered to be non-GAAP financial information, such as constant currency net sales, constant currency SG&A, free cash flow, and adjusted EBITDA, please see the notes in the appendix of our webcast slide and in the related reconciliations in the slides and earnings release posted on our website. I will now turn the call over to Matt Monahan.
Thank you, Louis, and good morning. Beginning on slide three, during the second quarter, we achieved sequential improvement in adjusted EBITDA as our strategic actions began to positively impact performance. In particular, the improved results were driven by lower STNA expense and strong improvement in gross margin due to increased pricing effectiveness and favorable product mix. While input costs remain high, we're seeing a greater impact from pricing actions as costs are somewhat less volatile. In addition, free cash flow turned positive, a significant improvement compared to both the prior year and sequentially. The improvement was driven by lower working capital as our cash conversion cycle improved, driven by improved cash collections and reduced inventory. Looking at revenue for the quarter, we achieved sequential growth in mobility and seating products driven by increased adoption of our compelling product portfolio. As a testament to our culture of innovation, we're proud to once again receive industry recognition in many categories for outstanding products and technology in our mobility and seating category. Sales of lifestyle and respiratory products were impacted by continuing component and supply chain challenges issues we are better positioned to address today and which I will discuss further momentarily. At the same time, we continue to experience elevated order backlog across all product categories and regions and see strong demand in mobility and feeding and lifestyles products. While backlog for respiratory products remains elevated, sales are anticipated to normalize in the next several quarters to pre-pandemic levels, giving less COVID-related demand for these products. Based on improvements in our business performance, we're pleased to have secured additional capital after second quarter, which provides increased liquidity and flexibility. We expect that strategic funding will enable us to more effectively work with our suppliers and find alternative solutions to short-term supply constraints, which will help us more quickly convert backlogged customer orders to sales and accelerate transformative plans to drive long-term profitability. We anticipate the additional liquidity will also enhance our transformation plans to optimize product portfolio, physical footprint, lower operating costs, and improve operating leverage. As we're in the early stages of deploying the additional capital, we look forward to providing updates in the coming quarters on how these actions are anticipated to drive profits and enhance shareholder value. Overall, we're seeing favorable trends across the business despite a challenging macroeconomic environment of cost and availability of inputs. While we have more work to do, we're confident that we have the right tools, the right team, and the right balance sheets to drive sustainable long-term results. I'll now turn the call over to Kathy, who will provide a more detailed financial summary.
You're reading a preview of the IVC Q2 2022 earnings call.
Free account.